ImmuPharma Chairman explains why the Avion deal is so significant

ImmuPharma plc (LON: IMM) Non-Executive Chairman Tim McCarthy joins DirectorsTalk to discuss a licencing and development agreement with US speciality pharmaceutical company Avion. Tim talks us through the key highlights of the deal, provides background on Avion, the importance of this validation from an industry player, partners for other territories, the next key milestones, the Lanstead Agreement and why ImmuPharma is now a stock potential investors should be considering.

ImmuPharma is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The company portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Immupharma Plc

    More articles like this

    Immupharma Plc

    Pregnancy outcomes greatly improved in lupus patients

    Historically, pregnancy in patients with systemic lupus erythematosus (SLE) was considered so risky that physicians counseled women to avoid becoming pregnant and recommended that women carrying a child terminate their pregnancy. Now, a new study published

    Immupharma Plc

    Immupharma PLC Subscription to raise £2.66 million

    Commenting, ImmuPharma’s Chairman, Tim McCarthy, said: “We are delighted to be welcoming back Lanstead as a significant shareholder of the Company. Lanstead has been very supportive of the Company since their first investment in 2016 and

    Immupharma Plc

    10 Surprising Autoimmune Disease Facts You Need to Know

    If it seems like everyone and her grandma knows someone with an autoimmune disease, that’s because the term is a giant bucket that holds some 80 conditions, some as well-known as multiple sclerosis or type 1 diabetes, and as

    Immupharma Plc

    Autoimmune Diseases That Are Different For Women Than Men

    Research is just starting to explore how different conditions affect female-bodied people differently to male-bodied people. One of these areas in particular is in autoimmune conditions, where the immune system treats healthy tissues and cells as

    Immupharma Plc

    Why Autoimmune Diseases Cause the Body to Attack Itself

    A new study published in the journal Cell explores the cellular “runaway train” that allows lupus and other autoimmune diseases to spread throughout the body. Autoimmune disease is exactly what it sounds like—the body mistakenly fighting

    Immupharma Plc

    Chairman Q&A with Tim McCarthy at ImmuPharma PLC (LON:IMM)

    ImmuPharma’s Tim McCarthy discusses their final results, spend going forward, corporate strategy for Lupuzor, Nucant & Ureka, key milestones for shareholders and the initiation note issued by The Life Sciences Division in this exclusive interview with DirectorsTalk

    Immupharma Plc

    World Lupus Day: new report reveals need for care improvements

    The initiative is in collaboration with a Global Multidisciplinary Steering Committee, and the report outlines three specific, patient-centred Calls to Action to the lupus community. The report urges that we need increased awareness of lupus amongst